Prosonix is focused on delivering performance-enhanced inhaled medicines to treat respiratory diseases (asthma and COPD), using its unique, proprietary DISCUS^® and UMAX^® particle engineering technologies. These technologies generate ‘smart' respiratory drug particles that are specifically designed to target the optimum site of action in the lung, precisely and consistently, to gain maximum clinical effect.

By controlling particle size, shape and form, Prosonix can develop superior drug formulations, offering more accurate dosing and enabling the use of simple cost-effective MDI and DPI devices. Its technologies have been applied successfully to many compounds for inhalation including inhaled corticosteroids (ICS), such as fluticasone and budesonide, long-acting muscarinic antagonists (LAMA), such as glycopyrrolate, long-acting beta-agonists (LABAs), such as salmeterol and formoterol, and other other inhaled drugs.

These ‘smart' medicines are anticipated to have important clinical advantages to patients over currently marketed products owing to their precise and predictable targeting to the site of action in the lung, such as:

• Improved dose consistency, eliminating variability

• Reduced dose with clinical comparability

• Maximised effectiveness of delivered dose

• Improved patient compliance

Targeting combination therapy, Prosonix can also generate novel and proprietary multi-component particles (MCP^TM) combining two or more drug molecules consistently in a pre-determined ratio in each and every particle in the formulation. The MCP^TM are fully co-associated and have been shown to facilitate co-localisation of active pharmaceutical components at the site of action, which in turn offers the potential for enhanced synergistic clinical effect.